IP Library › Granted Patent US 7,780,984
Granted Patent B2
US 7,780,984 · App. 11/880,314 · Granted Aug 24, 2010

Methods and compositions for treating proliferative diseases

Assignee: Abraxis Bioscience, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,780,984
App. No.
11/880,314
Granted
Aug 24, 2010
Kind
B2
Abstract

The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.

Claims (11)

1. A method of treating a cancer disease in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising 17-AAG and an albumin, wherein the nanoparticles comprise 17-AAG coated with the albumin.

2. The method according to claim 1 , wherein the cancer is lung cancer.

3. The method according to claim 1 , wherein the 17-AAG is administered intravenously.

4. The method according to claim 1 , wherein the albumin is human serum albumin.

5. The method according to claim 1 , wherein the average diameter of the nanoparticles in the composition is no greater than 200 nm.

6. The method according to claim 1 , wherein the weight ratio of the albumin to 17-AAG in the composition is less than 18:1.

7. The method according to claim 4 , wherein the average diameter of the nanoparticles in the composition is no greater than 200 nm.

8. The method according to claim 7 , wherein the weight ratio of the albumin to 17-AAG in the composition is less than 18:1.

9. The method according to claim 1 , wherein the composition does not induce significant side effects.

10. The method according to claim 5 , wherein the average diameter of the nanoparticles in the composition is no greater than 100 nm.

11. The method according to claim 6 , wherein the weight ratio of the albumin to 17-AAG in the composition is about 3:1 to about 12:1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2009
From: DESAI, NEIL P.; SOON-SHIONG, PATRICK
To: ABRAXIS BIOSCIENCE, INC.
Reel/Frame 022305/0320 →
MERGER Recorded Feb 24, 2009
From: ABRAXIS BIOSCIENCE, INC.
To: ABRAXIS BIOSCIENCE, LLC
Reel/Frame 022305/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2007
From: DESAI, NEIL P.; SOON-SHIONG, PATRICK; DE, TAPAS
To: ABRAXIS BIOSCIENCE, INC.
Reel/Frame 020146/0306 →
Continuity (4)
Division 1154424200 · Oct 6, 2006
Continuation 1135928600 · Feb 21, 2006
Provisional Application 6065424500 · Feb 18, 2005
Related Publication 20080063724A1 · Mar 13, 2008